Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyladenine SCHEMBL152593 | 0.81 | LRRK2 (0.52) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL29804812 | 0.81 | HTT (0.36) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL6517684 | 0.79 | LRRK2 (0.42) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| Dimethyladenine SCHEMBL28476806 | 0.79 | LRRK2 (0.50) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| Dimethyladenine SCHEMBL11157543 | 0.79 | LRRK2 (0.50) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL29100435 | 0.78 | LRRK2 (0.41) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL10700195 | 0.78 | CHEK1 (0.37) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL5019515 | 0.76 | HTT (0.41) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL5019519 | 0.75 | HSD17B10 (0.39) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL21814339 | 0.74 | HTT (0.58) | CHEK1AURKALRRK2PDPK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3561077-B1 | METHODS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER LAB (FR) | 2022-12-21 | — | — | EP | disclosed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| US-20100272721-A1 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100113294-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2137655-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | Momenta Pharmaceuticals, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080292622-A1 | METHODS OF EVALUATING PATIENTS | BIOGEN IDEC MA INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080279853-A1 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008128230-A1 | REFERENCE GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008128227-A1 | DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007038264-A2 | GAPR-1 METHODS | BIOGEN IDEC MA INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006138219-A2 | METHODS OF DIAGNOSIS / PROGNOSIS OF INFLAMMATORY CONDITIONS | BIOGEN IDEC MA INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006130429-A2 | TREATMENT OF CANCER | BIOGEN IDEC MA INC. (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | NTRK1, NTRK3, NTRK2 | CHEK1 1558/4885AURKA 810/4885LRRK2 1432/4885 |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | CHEK1 2068/4885AURKA 1025/4885LRRK2 1905/4885 |
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | CHEK1 476/4885AURKA 4246/4885LRRK2 3143/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | CHEK1 4235/4885AURKA 3234/4885LRRK2 2879/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | CHEK1 476/4885AURKA 4246/4885LRRK2 3143/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | CHEK1 4235/4885AURKA 3234/4885LRRK2 2879/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | CHEK1 4260/4885AURKA 3122/4885LRRK2 3220/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | CHEK1 4235/4885AURKA 3234/4885LRRK2 2879/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | CHEK1 4260/4885AURKA 3122/4885LRRK2 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.